Evidence map›Paper›PMID 33549124›Full record

ArticleJournal of translational medicine2021

Gender-specific associations between polymorphisms of the circadian gene RORA and cutaneous melanoma susceptibility.

Clara Benna, Senthilkumar Rajendran, Giovanna Spiro, Chiara Menin, Luigi Dall'Olmo, Carlo Riccardo Rossi, Simone Mocellin

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Circadian clock and cancer.Military Medical Research · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Clara BennaDepartment of Surgery Oncology and Gastroenterology, University of Padova, Padova, Italy. clara.benna@unipd.it.ORCID 0000-0002-9077-2471
Senthilkumar RajendranDepartment of Surgery Oncology and Gastroenterology, University of Padova, Padova, Italy.
Giovanna SpiroDepartment of Surgery Oncology and Gastroenterology, University of Padova, Padova, Italy.
Chiara MeninImmunology and Diagnostic Molecular Oncology Unit, Veneto Institute of Oncology (IOV - IRCCS), Padova, Italy.
Luigi Dall'OlmoDepartment of Surgery Oncology and Gastroenterology, University of Padova, Padova, Italy.
Carlo Riccardo RossiDepartment of Surgery Oncology and Gastroenterology, University of Padova, Padova, Italy.
Simone MocellinDepartment of Surgery Oncology and Gastroenterology, University of Padova, Padova, Italy.
University of Padua · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMelanoma is the deadliest of skin cancers and has an increasing annual incidence worldwide. It is a multi-factorial disease most likely arising from both genetic predisposition and environmental exposure to ultraviolet light. Genetic variability of the components of the biological circadian clock is recognized to be a risk factor for different type of cancers. Moreover, two variants of a clock gene, RORA, have been associated with melanoma patient's prognosis. Our aim is to test the hypothesis that specific single nucleotide polymorphisms (SNPs) of the circadian clock genes may significantly influence the predisposition to develop cutaneous melanoma or the outcome of melanoma patients.

methodsWe genotyped 1239 subjects, 629 cases of melanoma and 610 healthy controls in 14 known SNPs of seven selected clock genes: AANAT, CLOCK, NPAS2, PER1, PER2, RORA, and TIMELESS. Genotyping was conducted by q-PCR. Multivariate logistic regression was employed for susceptibility of melanoma assessment, modeled additively. Subgroup analysis was performed by gender. For the female subgroup, a further discrimination was performed by age. For prognosis of melanoma assessment, multivariate Cox proportional hazard regression was employed. The Benjamini-Hochberg method was utilized as adjustment for multiple comparisons.

resultsWe identified two RORA SNPs statistically significant with respect to the association with melanoma susceptibility. Considering the putative role of RORA as a nuclear steroid hormone receptor, we conducted a subgroup analysis by gender. Interestingly, the RORA rs339972 C allele was associated with a decreased predisposition to develop melanoma only in the female subgroup (OR 0.67; 95% CI 0.51-0.88; P = 0.003) while RORA rs10519097 T allele was associated with a decreased predisposition to develop melanoma only in the male subgroup (OR 0.62; 95% CI 0.44-0.87; P = 0.005). Moreover, the RORA rs339972 C allele had a decreased susceptibility to develop melanoma only in females aged over 50 years old (OR 0.67; 95% CI 0.54-0.83; P = 0.0002). None of the studied SNPs were significantly associated with the prognosis.

conclusionsOverall, we cannot ascertain that circadian pathway genetic variation is involved in melanoma susceptibility or prognosis. Nevertheless, we identified an interesting relationship between melanoma susceptibility and RORA polymorphisms acting in sex-specific manner and which is worth further future investigation.

Indexed as

MelanomaSkin NeoplasmsAllelesCircadian RhythmFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedNuclear Receptor Subfamily 1, Group F, Member 1Polymorphism, Single NucleotideNuclear Receptor Subfamily 1, Group F, Member 1RORA protein, humanCircadian clockCutaneous melanomaNuclear receptorPrognosisRORASingle nucleotide polymorphismsSNPSteroid hormoneSusceptibility

Identifiers

PMID33549124
PMCPMC7866430
OpenAlexW3126323127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.